CAPR Shareholders: Capricor Therapeutics Clinical Data News Triggers Securities Fraud Class Action for Investors – Contact BFA Law if You Lost Money
Plaintiff firm Bleichmar Fonti & Auld LLP announced a securities fraud class action against Capricor Therapeutics and certain senior executives, pending in the U.S. District Court for the Southern District of California with a lead plaintiff deadline of September 28, 2026. The complaint alleges Capricor made false statements about Deramiocel and the integrity of the clinical data supporting its BLA, including undisclosed post-hoc changes to the pre-specified statistical analysis plan that the FDA had not approved before resubmission.
Key figures
- Court
- U.S. District Court for the Southern District of California, No. 26-cv-04385
- Adcom vote
- 9-3 non-binding vote that evidence did not support Deramiocel efficacy
- Close jul29
- $6.57
- Close jul30
- $4.19
- Stock drop pct
- 64.5%
- Second drop pct
- 36%
- Close after drop
- $7.00
- Close before drop
- $19.70
- Stock drop per share
- $12.70
- Second drop per share
- $2.38
- Lead plaintiff deadline
- September 28, 2026
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.